MITIGATE
Closed-loop Molecular Environment for Minimally Invasive Treatment of Patients with metastatic Gastrointestinal Stromal Tumours
| Coordinatore | RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 5˙848˙215 € |
| EC contributo | 4˙494˙253 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2017-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Organization address
address: SEMINARSTRASSE 2 contact info |
DE (HEIDELBERG) | coordinator | 1˙553˙768.00 |
| 2 |
EIBIR GEMEINNUETZIGE GMBH ZUR FOERDERUNG DER ERFORSCHUNG DER BIOMEDIZINISCHEN BILDGEBUNG
Organization address
address: Neutorgasse 9/2 contact info |
AT (VIENNA) | participant | 464˙000.00 |
| 3 |
Advanced Accelerator Applications
Organization address
address: Rue Diesel 20 contact info |
FR (Saint Genis Pouilly) | participant | 449˙640.00 |
| 4 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 405˙422.00 |
| 5 |
MEDIZINISCHE UNIVERSITAET INNSBRUCK
Organization address
address: Christoph-Probst Platz 1 contact info |
AT (INNSBRUCK) | participant | 341˙400.00 |
| 6 |
RAPID BIOMEDIZINISCHE GERATE RAPID BIOMEDICAL GMBH
Organization address
address: KETTELERSTRASSE 3-11 PAV 2-4 contact info |
DE (RIMPAR) | participant | 329˙488.00 |
| 7 |
STEMCELL TECHNOLOGIES SARL
Organization address
address: MINIPAR POLYTEC RUE DES BERGES 40 contact info |
FR (GRENOBLE) | participant | 312˙320.00 |
| 8 |
CAGE CHEMICALS SRL
Organization address
address: VIA BOVIO 6 contact info |
IT (NOVARA) | participant | 307˙795.00 |
| 9 |
HOCHSCHULE MANNHEIM
Organization address
address: WINDECKSTRASSE 110 contact info |
DE (MANNHEIM) | participant | 229˙500.00 |
| 10 |
UNIVERSITA DEGLI STUDI DI TORINO
Organization address
address: Via Giuseppe Verdi 8 contact info |
IT (TORINO) | participant | 100˙920.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
Gastrointestinal stromal tumours (GIST) are a rare disease that metastasises in up to 85% of patients with subsequent median progression-free survival (PFS) of only around 30 months. Tumours are characterised by activating mutations in the KIT or the PDGFRA gene and therefore treatment is mainly based on tyrosine kinase inhibitors designed to block these mutated receptors. However, drug resistance is often based on mutations changing the conformity of the receptor, leaving little effective therapeutic options to these patients. To date, second line chemotherapy offers a median PFS of 6-9 months and external beam radiotherapy is limited by organs at risk close to the tumour. Alternative approaches such as endoradiotherapy or minimally-invasive ablation techniques are effective for local control but are inconsistently used and are not tailored to the individual patient's type of disease. To address these issues, we propose a closed-loop personalised treatment concept combining endoscopic-assisted tissue sampling, inline biotechnology and targeted molecular PET imaging probe development combined with minimally-invasive treatment monitored by new functional and metabolic MR imaging techniques. A consistent value chain across European academic centres, research institutes and SMEs will be established for mass spectrometry of tumours, linkage of radiochemical molecular imaging probes, design of new immunocompromised animal models and targeted therapeutic radiopharmaceuticals. This closed-loop platform will minimise fragmentation of treatment approaches by a coherent molecular-based multimodality concept, thus providing new treatment options. On a larger scale, the MITIGATE platform can be expanded to further patient cohorts with oligometastatic diseases such as other sarcomas or renal cell carcinoma. For SMEs the access to new animal models and ligands along with translation into clinical practice will strengthen their market share for new probes and imaging technology.